Signos Introduces First FDA-Cleared Glucose Monitoring System for Weight Management

Signos, a metabolic health platform, has launched the first FDA-cleared glucose monitoring system for weight management. The system uses a continuous glucose monitor (CGM) and AI-driven platform to provide personalized insights into how food, movement, sleep, stress, and more affect each individual's body. The system aims to help people take control of their health and make decisions backed by their biology.

Signos, a metabolic health platform, has recently launched the first FDA-cleared glucose monitoring system specifically designed for weight management. The system leverages a continuous glucose monitor (CGM) and an AI-driven platform to provide personalized insights into how various factors, such as food, movement, sleep, and stress, affect an individual's body. This innovative approach aims to empower users to make data-driven decisions that improve their overall health and well-being.

The Signos system utilizes an AI platform and an off-the-shelf CGM from Dexcom to offer real-time data and personalized lifestyle recommendations. This technology can be used in combination with or after other existing weight loss treatments, such as GLP-1s or bariatric surgery, providing a comprehensive solution for weight management [1].

The system is accessible to any patient, regardless of their weight or BMI, and is currently priced at $139 for a three-month plan and $129 for a six-month plan. This affordability makes it a viable option for those seeking to manage their weight without the high costs and limited accessibility of traditional weight loss treatments [1].

The approval of this system by the FDA marks a significant milestone in the fight against obesity. The obesity epidemic costs the U.S. healthcare system over $170 billion annually, and with nearly 74% of Americans being overweight or obese, there is a pressing need for innovative solutions [1].

Signos aims to make a substantial impact on the obesity curve and improve the health of many Americans. The company is actively working with health insurance companies and employers to secure coverage for the system, with the expectation that interest in tackling weight issues will continue to grow [1].

The system's AI platform uses glucose data, meal logs, and workout history to suggest appropriate food choices and physical activities. This real-time guidance helps users understand their body's responses and make informed decisions to support long-term weight management and overall health [2].

While the exact number of current users is not disclosed, Signos has scaled its operations to handle a substantial increase in demand following the FDA approval. The company is well-positioned to capitalize on the growing interest in metabolic health and weight management solutions [1].

In conclusion, the launch of Signos' FDA-cleared glucose monitoring system represents a significant advancement in the field of weight management. By providing personalized, data-driven insights, the system offers a promising solution for individuals seeking to improve their health and manage their weight effectively.

References:
[1] https://www.cnbc.com/2025/08/20/fda-approves-signos-glucose-monitoring-for-weight-loss.html
[2] https://www.signos.com/